Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CureVac, Crucell in Flu Vax Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

CureVac, Crucell in Flu Vax Development Pact

To develop a vaccine based on RNActive technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CureVac has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. under which CureVac will collaborate with Crucell Holland B.V. (a Janssen Pharmaceutical member company) on the development of an flu vaccine based on CureVac’s RNActive technology. CureVac’s technology platform with RNActive vaccines has demonstrated effectiveness and safety in several clinical trials.
 
CureVac will develop optimized RNActive vaccines based on Crucell’s proprietary antigen sequences, which will be tested in various models. Additional details were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics